Now I have sufficient calibration data. Let me write the final consolidated review.

## Summary

This paper introduces the problem of *PPI candidate ranking* — given a target protein and its known interaction partners, rank novel candidate proteins by predicted likelihood of interaction. The authors propose a two-stage framework: (1) an interpretability-guided retrieval stage that uses predicted contact maps from D-SCRIPT/Topsy-Turvy to focus cosine similarity on "active" embedding regions of known partners, and (2) a re-ranking stage incorporating multiple signals (interaction scores, structural plausibility via pDockQ, semantic/LLM-based scores). Evaluation is on a prospective STRING v11→v12 temporal split. The core idea — exploiting model interpretability for ranking rather than explanation — is creative, and the temporal evaluation design is a genuine improvement over static PPI classification benchmarks. However, the evaluation contains two structural flaws that prevent the central claims from being accepted as stated.

## Strengths

1. **Novel problem formulation with prospective evaluation design.** The paper formalizes PPI candidate ranking using known partners (KP(p)) and unknown partners (NP(p)) from consecutive STRING releases (v11→v12). This temporal split creates a forward-looking test set, directly addressing the limitation that "existing PPI benchmarks are largely static and retrospective." This is a practically motivated and methodologically sound evaluation design.

2. **Creative use of interpretability for retrieval.** Rather than treating model interpretability as an explanation tool, the paper exploits predicted contact maps C(p,p_k) to identify active residue regions and focuses similarity computations there (Eqs. 3-4, Figure 1). This is a genuine methodological innovation. Table 1 shows this approach yields substantially better early recall: for D-SCRIPT, Recall@10 rises from 0.0124 (raw prediction probability) to 0.2641, and MRR increases from 0.0340 to 0.1685.

3. **Large-scale evaluation with substantial real improvements.** The interpretability-guided method consistently improves nearly all ranking metrics across three state-of-the-art backbones (D-SCRIPT, Topsy-Turvy, xCAPT5). For D-SCRIPT, Success@5 goes from 0.0000 to 0.0778, and Average Rank drops from 482.86 to 239.77. The absolute improvements at early ranks (Recall@5 from 0.7% to 18.3%) are practically meaningful for experimental screening.

4. **Systematic multi-source re-ranking with careful temporal/lackage controls.** Section 4.2 integrates seven distinct signals (interaction score, pDockQ, TF-IDF, token/term/location overlap, and three LLM-based methods). The cross-encoder PubMedBERT is fine-tuned exclusively on STRING v11 with GroupKFold splits by protein identity and evaluated on disjoint v12 interactions, preventing protein-level leakage. The pairwise rank-shift analysis in Table 2 provides fine-grained comparisons showing which complementary evidence sources are most effective (e.g., PubMedBERT improves or maintains 75.5% of rediscoveries vs. the cosine baseline).

## Weaknesses

### Fatal
None.

### Major

1. **Missing baselines that also use known partner information.** Tables 1 and the abstract's performance claims compare the proposed method (which explicitly uses known interactors KP(p) as anchors) against raw prediction probabilities of D-SCRIPT, Topsy-Turvy, and xCAPT5 — none of which are given access to those known interactors. Since the problem definition states that known partners are available, the relevant comparison is against methods that also leverage KP(p): e.g., ranking candidates by the average or maximum baseline interaction score over known partners, or retraining a classifier that incorporates this information. Without such controls, the reported gains conflate "using known partners helps" with "the specific interpretability-guided retrieval mechanism is superior." This undermines the central quantitative claim that the proposed method, rather than any reasonable use of known partners, drives the improvement.  

   *Why this matters:* A reviewer or practitioner cannot tell from the current evidence whether the 25× improvement in Recall@5 is due to the contact-map-guided similarity or simply because the method has access to information the baselines lack. Adding baselines that also use KP(p) (even through simple averaging or max-pooling of scores) is necessary to attribute the gains.

2. **Re-ranking evaluation does not demonstrate overall improvement in prioritization.** The re-ranking analysis (Table 2) operates on the top-10 candidates that *already* contain a true novel partner from the first-stage ranking. It measures rank-shifts among already-retrieved positives, but does **not** evaluate: (a) whether re-ranking introduces *new* correct candidates missed in the first stage, (b) how it affects global recall@k, precision@k, or NDCG across the full candidate list, or (c) whether improvements on the already-retrieved subset translate to better overall screening. The conclusion that the refinement step "improves prioritization" is only weakly supported — the experiment is confined to a small, positively-biased slice of the data.

   *Why this matters:* In a practical screening pipeline, what matters is whether re-ranking surfaces more true partners overall, not just whether it reorders already-correct predictions. The current analysis answers only the latter question.

### Minor

3. **"Two orders of magnitude" is an exaggeration.** The abstract and conclusion claim "improvements … by up to two orders of magnitude." The largest relative improvement in Table 1 is Recall@5 (~26× for D-SCRIPT). MRR improves ~5×, Average Rank ~2×. No metric reaches 100×. The real improvements are substantial and practically meaningful; the hyperbolic framing misrepresents the actual numbers and should be corrected.

4. **No method to combine re-ranking signals into a single final ranking.** Section 4.2 evaluates ten signals independently (each produces its own ranking), but the paper never specifies how to integrate them into a single usable output. A practitioner seeking to apply the pipeline is left without guidance on which signal(s) to trust or how to combine them (e.g., weighted sum, stacking, majority vote). The paper presents 10 separate re-ranking methods without completing the pipeline.

5. **Prediction Coverage metric is confusingly presented.** In Table 1, "Prediction Coverage" is defined as "Total number of true novel partners that are successfully retrieved across all proteins" but displayed as a fraction between 0 and 1 (e.g., 0.9544 for D-SCRIPT raw). This appears to be a *fraction* of all novel partners retrieved across the full (untruncated) ranking, not a total count. The label and definition should be made consistent.

6. **No statistical significance or variance reported.** Table 1 reports single values without confidence intervals, error bars, or significance tests. Given the dataset size and the practical importance of the claims, some measure of variability (e.g., bootstrapped CIs, performance stratified by protein properties) would strengthen the evidence.

7. **No stratification by number of known partners.** The method's reliance on KP(p) means its effectiveness likely varies with |KP(p)|. The paper acknowledges this as a limitation (proteins with few or no known partners) but does not report performance broken down by, e.g., |KP(p)| in {1–2, 3–5, 6+}. This would help readers understand when the method works and when it reduces to generic prediction.

### Trivial

- The text contains a few parser artifacts (e.g., "One of the most widely adopted An example" in Section 3, "a the two-stage framework" in Section 4) that do not hinder understanding.
- The sliding-window assumption in Eq. (3) (contiguous interface region) is a design decision that could benefit from ablation (e.g., comparing against global average pooling or multiple-segment aggregation), but is not a critical flaw given the overall positive results.

## Nice-to-Haves

- **Ablation of active-region selection** (single contiguous segment vs. all high-activation residues vs. whole embedding) to validate the design choice in Eq. (3).
- **Evaluation on proteins with few known partners** to quantify when the method adds value versus when it defaults to raw prediction probabilities.
- **Re-ranking evaluation on the full candidate list** (global recall@k, precision@k, NDCG) rather than only the top-10 already-correct subset.
- **Example case studies** showing top-10 rankings before/after re-ranking with true positives highlighted, to illustrate how the method works in practice.

## Removed Points
*These points were flagged by reviewers but are removed from the main review for the following reasons:*

- *Criticism that "some LLM gains may reflect latent knowledge of interactions from training data":* This is speculative — the paper explicitly controls for protein-level data leakage via GroupKFold and temporal v12 evaluation. No concrete evidence of leakage is presented.
- *Criticism that D-SCRIPT was chosen arbitrarily for re-ranking analysis:* The paper justifies this choice empirically (D-SCRIPT shows better early-rank performance than Topsy-Turvy, making it the more relevant backbone for top-k prioritization).
- *Strength about "two-orders-of-magnitude improvement":* This is retained as a factual finding (large improvements) but the specific numerical claim is addressed as an exaggeration in Weaknesses.
- *Request for prospective wet-lab validation:* This is outside the scope of a computational methods paper; valuable as future work but not a weakness of the current submission.
- *Various formatting, typo, and presentation nitpicks:* These are parser artifacts or below the threshold of substantive criticism.

## Novel Insights

Beyond the paper's own contributions, the pairwise rank-shift analysis in Table 2 yields a non-obvious finding: lightweight semantic signals (TF-IDF, token/term/location overlap) often match or exceed the re-ranking performance of computationally expensive LLMs (BioBERT, BioMedRoBERTa) at a fraction of the cost. This suggests that for PPI candidate ranking, curated functional annotations capture much of the same signal that dense biomedical embeddings provide. This is a practical insight for practitioners: simple annotation-based re-ranking may be sufficient for many screening applications, without the overhead of LLM inference.

## Suggestions

1. **Add baselines that use known partners.** For each backbone method (D-SCRIPT, Topsy-Turvy, xCAPT5), add a baseline that ranks candidates by max or average interaction score over known partners. This controls for the most obvious confound and would allow the paper to make a clean attribution claim.
2. **Evaluate re-ranking on the full candidate list.** Report how re-ranking changes recall@k, precision@k, and NDCG for the complete candidate pool, not just the top-10 already-correct subset.
3. **Correct the "two orders of magnitude" claim** in the abstract and conclusion to accurately reflect the measured improvements (~5–26×).
4. **Clarify Prediction Coverage** as a fraction (not total count) and ensure the definition is consistent.
5. **Propose a method for combining re-ranking signals** into a single final ranking, even a simple heuristic (e.g., rank aggregation via Borda count or a learned weighted sum).
6. **Report stratified results by |KP(p)|** to characterize when the method is most and least effective.

## Score and Decision

**Calibration anchors** (all from the deepreview_13k_calibration set):

| Path | Avg Score | Comparison |
|------|-----------|------------|
| `jPrKs5rOWw.md` (Refine-PPI) | 3.50 | Weaker paper — unclear contributions, poor presentation, narrow experiments. The paper under review is better written and has a clearer evaluation design. |
| `ifK9NFyrhn.md` (Disconnecting The Dots) | 3.50 | Niche methodology contribution with limited broader impact. The paper under review addresses a more practically relevant problem. |
| `eh1fL0zw8o.md` (LLaPA) | 6.00 | Also has unfair comparison concerns (graph baselines nerfed by test edge removal) and questions about LLM necessity. Similar severity of evaluation issues. The paper under review is comparable — interesting method, undermined by evaluation. |
| `itGkF993gz.md` (MAPE-PPI) | 5.67 | Accepted — solid method, systematic experiments, but some reviewers raised replication and novelty concerns. The paper under review has more severe evaluation gaps. |
| `xcMmebCT7s.md` (PPIformer) | 5.80 | Accepted — strong dataset contribution (PPIRef), clear experiments, but also had missing variance/baseline concerns. The paper under review has a weaker evaluation baseline. |
| `87B3zDRMjv.md` (RankNovo) | 5.50 | Rejected — modest improvements, heavy dependence on base models. Similar in having a core contribution weakened by evaluation issues. |
| `tcsZt9ZNKD.md` (Sparse Autoencoders) | 8.20 | Very strong — clear scaling laws, rigorous evaluation, broad impact. The paper under review is not at this level of rigor. |

**Comparative assessment:** The paper introduces a genuinely interesting problem and a creative method. The prospective v11→v12 evaluation is a meaningful improvement over static PPI benchmarks. However, the evaluation has two structural issues that prevent the central claims from being accepted: the baselines lack access to known partner information (conflating two sources of improvement), and the re-ranking analysis is confined to an already-correct subset. These are not fatal flaws — the method may well be superior to reasonable baselines — but the current evidence does not establish this. The exaggeration of "two orders of magnitude" further weakens the paper's credibility. Relative to the anchors, this paper is somewhat above the purely weak papers (score ~3.5) but below papers that cleanly demonstrate their claims (score ~5.5–6.0). The need for substantial revisions to the evaluation places it in the reject range.

**Score:** 4.5  
**Decision:** Reject

MY FINAL SCORE: <score>4.5</score>
MY FINAL DECISION: <decision>Reject</decision>